36 completed, 7 unknown, 6 recruiting, 6 withdrawn. 17 Phase 2, 13 Phase 3, 13 Phase 4, 10 Not applicable, 8 Phase 1.
Follow Tardive Dyskinesia: new trials by email Literature Review of Tardive Dyskinesia trials Research Report on Tardive Dyskinesia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms Computer-Assisted Objective Assessment of Extrapyramidal Symptoms - Extrapyramidal Symptoms, Drug-induced Parkinsonism | Not yet recruiting | Shanghai Mental Health Center | 180 | 2026-07-01 | 2026-07-21 | |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities Deutetrabenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-06-22 | 2026-07-06 |
| Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia NBI-1065890, Placebo - Tardive Dyskinesia | Phase 2 | Recruiting | Neurocrine Biosciences | 100 | 2026-02-06 | 2026-06-23 |
| Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD repetitive Transcranial Magnetic Stimulation - Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation | Not applicable | Recruiting | Peking University Sixth Hospital | 62 | 2025-09-08 | 2025-12-05 |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Neurocrine Biosciences | 100 | 2025-08-29 | 2026-09-18 |
| Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients Tardive Dyskinesia | Not yet recruiting | Power Life Sciences Inc. | 500 | 2025-02-01 | 2024-01-23 | |
| Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia LPM3770164 sustained release tablet 5 mg, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg - Tardive Dyskinesia (TD) | Phase 1 / Phase 2 | Recruiting | Luye Pharma Group Ltd. | 120 | 2025-01-14 | 2025-01-22 |
| Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities Valbenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Withdrawn | Stephen Ruedrich | 2025-01-01 | 2024-10-24 | |
| Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine Valbenazine - Tardive Dyskinesia | Phase 1 | Withdrawn | Yale University | 2024-10-18 | 2025-07-11 | |
| Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets LPM3770164 sustained release tablet - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 16 | 2024-07-31 | 2024-12-12 |
| Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Tardive Dyskinesia, Huntington Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 40 | 2023-12-19 | 2024-12-12 |
| Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes TDtect - Tardive Dyskinesia | Not applicable | Unknown | iRxReminder | 300 | 2023-05-30 | 2024-03-12 |
| Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | Neurocrine Biosciences | 59 | 2023-05-09 | 2026-01-16 |
| A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 104 | 2022-02-25 | 2024-01-29 |
| Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Valbenazine, Placebo oral capsule - Tardive Dyskinesia (TD) | Phase 4 | Completed | Neurocrine Biosciences | 135 | 2019-03-18 | 2021-04-20 |
| Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Varenicline - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Corporal Michael J. Crescenz VA Medical Center | 10 | 2019-01-01 | 2019-03-22 |
| Pimavanserin Treatment in TS Pimavanserin - Tourette Syndrome, Tardive Dyskinesia | Early Phase 1 | Completed | Joseph Jankovic | 10 | 2018-11-12 | 2021-03-12 |
| The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Valbenazine, Placebo oral capsule - Tardive Dyskinesia (TD) | Phase 4 | Completed | Neurocrine Biosciences | 89 | 2018-09-14 | 2020-06-04 |
| Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia Pyridoxine, Placebo - Tardive Dyskinesia, Antipsychotic Agents | Not applicable | Completed | University of North Carolina, Chapel Hill | 17 | 2017-12-01 | 2023-03-14 |
| Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Propranolol Hydrochloride, Placebo Oral Tablet - Tardive Dyskinesia | Phase 2 / Phase 3 | Withdrawn | Emory University | 2017-09-18 | 2019-02-26 |
Showing 20 of 61. Sign in to see all of them.
Schizophrenia (17) · Movement Disorders (10) · Psychotic Disorders (7) · Dyskinesias (6) · Huntington Disease (4) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Central Nervous System Diseases (3) · Intellectual Disability (3) · Nervous System Diseases (3) · Bipolar Disorder (2) · Caregiver Burden (2) · Depressive Disorder, Major (2) · Developmental Disabilities (2)
Pathological Conditions, Signs and Symptoms (61) · Dyskinesia, Drug-Induced (59) · Central Nervous System Diseases (58) · Nervous System Diseases (58) · Neurologic Manifestations (57) · Signs and Symptoms (57) · Dyskinesias (55) · Movement Disorders (51) · Mental Disorders (24) · Schizophrenia Spectrum and Other Psychotic Disorders (17) · Basal Ganglia Diseases (7) · Brain Diseases (7) · Behavior (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5)
valbenazine (13) · deutetrabenazine (4) · Olanzapine (3) · Aripiprazole (2) · Pyridoxine (2) · Risperidone (2) · Transcranial Magnetic Stimulation (2) · Acamprosate (1) · Amisulpride (1) · Asian ginseng (1) · Deep Brain Stimulation (1) · Eicosapentaenoic Acid (1) · Fish Oils (1) · Galantamine (1) · Ginkgo biloba extract (1)
Neurocrine Biosciences (13) · Luye Pharma Group Ltd. (4) · Auspex Pharmaceuticals, Inc. (3) · Beersheva Mental Health Center (2) · Beijing HuiLongGuan Hospital (2) · Emory University (2) · Shanghai Mental Health Center (2) · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan (2) · Yale University (2) · Caroff, Stanley N., M.D. (1) · Centre Hospitalier Universitaire, Amiens (1) · Charite University, Berlin, Germany (1) · Corporal Michael J. Crescenz VA Medical Center (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GGZ Centraal (1)
United States (31) · China (10) · Canada (7) · Puerto Rico (6) · Germany (4) · Taiwan (4) · Czechia (3) · Israel (3) · Poland (3) · Slovakia (3) · France (2) · Hungary (2) · India (1) · Japan (1) · Netherlands (1)
Chris O'Brien, MD (4) · Stanley N Caroff, MD (2) · Stephen Ruedrich, MD (2) · Andreas R Kupsch, MD (1) · Andres Lozano, MD (1) · Chia-Hsiang Chan, M.D. (1) · Christopher O'Brien, MD (1) · Dilip V. Jeste, MD (1) · Dongfeng Zhou, Professor (1) · Gary J. Remington, MD, PhD (1) · Guangzhong Yin, MD (1)
PMID 31617235, PMID 38557959, PMID 28404690, PMID 40265997, PMID 17388711, PMID 17685739, PMID 18312060, PMID 20441726, PMID 20868638, PMID 28320223, PMID 28668671, PMID 28747452, PMID 29141124, PMID 30249417, PMID 30695293, PMID 31296586, PMID 32419679, PMID 32651242, PMID 35995551, PMID 36114799, PMID 37620825, PMID 37722831, PMID 38421921, PMID 39186921
2014 (2), 2025 (1), R01HD034027 (1), R01MH059101 (1), R43MH114763 (1)